Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC

Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC is a phase 2, interventional study registered as NCT06599827 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 54 participants, started 2024-09-20 and due to reach its primary completion in 2026-09-20. Interventions recorded: moderately hypofractionated radiotherapy; chemotherapy; immunotherapy; Total mesorectal excision (TME) surgery. Conditions listed: Rectal Cancer. Primary outcome: pathologic complete response (pCR). Colorectal eligibility wording from the registry: "MRI-confirmed rectal adenocarcinoma with the lower edge of the lesion ≤10cm from the anal verge". Sites: China. No results are recorded here; the registry entry is the source.